【何亚东】: 各位记者朋友： 大家下午好，欢迎参加商务部例行新闻发布会。今天我没有需要向大家通报的信息。 下面请提问。 【封面新闻记者】: 2021年7月，国务院批准率先在上海、北京、广州、天津、重庆五个城市，开展国际消费中心城市培育 建设。到目前正好满4周年，能否介绍培育建设取得了哪些亮点和成效？ 【何亚东】: 正像你刚才提到的，国际消费中心城市培育建设正好满4周年，4年来这项工作取得了积极成效，我在这 里分享一组数据：五个城市社零总额占全国的比重超过1/8，国家级示范步行街数量占全国的1/4，中华 老字号数量约占1/3，消费品进口占比达一半以上，离境退税销售额占七成左右。打开来看，可以从四 个维度来看待。 第一个维度是"国际"，体现在国际消费环境更加友好。五个城市着力提升支付便利化水平，优化离境退 税服务，积极打造国际友好消费环境，让外国朋友愿意来、方便购。特别是今年4月《关于进一步优化 离境退税政策扩大入境消费的通知》发布以来，北京、上海退税商店总数均超过1400家，广州突破500 家，带动上半年全国离境退税销售额增长94.6%，"中国购"成为热词。 第二个维度是"消费"，体现在消费引领力全面提升。五个 ...

Core Viewpoint - Haiwang Bio announced the termination of its nearly three-year plan to change its controlling rights, marking a pause in its efforts to introduce state-owned capital from Guangdong Province [1][4] Financial Performance - As of June 6, Haiwang Bio's stock price closed at 2.56 yuan per share, with a year-to-date increase of only 0.39%, resulting in a total market capitalization of 6.736 billion yuan [3] - The company has reported continuous losses for three consecutive years, with cumulative losses exceeding 3.7 billion yuan from 2022 to 2024. The first quarter of 2025 showed a 44.38% year-on-year decline in net profit to 23.72 million yuan, with an actual loss of 74.74 million yuan after excluding non-recurring gains and losses [4][6] Financial Structure - As of March 2025, the company's debt-to-asset ratio rose to 89.76%, significantly higher than the industry average in pharmaceutical distribution. Short-term debt reached 13.043 billion yuan, while cash and cash equivalents were only 4.565 billion yuan, indicating ongoing pressure on short-term debt repayment capabilities [6] - Accounts receivable reached 15.367 billion yuan, exceeding 200% of the current operating revenue, leading to tight operating capital and high collection risks due to long-term occupation of funds by hospital clients [6] Future Development and Restructuring - In the first half of 2024, the company faced 109 lawsuits related to accounts receivable, with a total amount exceeding 535 million yuan. The company recorded goodwill impairment of over 800 million yuan in 2023 and expects to continue impairing between 400 million to 570 million yuan in 2024, maintaining a goodwill balance of 863 million yuan by year-end [7] - The company plans to focus on resource integration and market expansion in the medical device sector, aiming to optimize its industrial layout and deepen strategic cooperation for business transformation and upgrading [8]

Core Viewpoint - The company has decided to terminate its plan for a specific issuance of A-shares for 2024 after discussions with strategic investors, indicating a strategic adjustment in its operations [1][2]. Group 1: Termination of A-share Issuance - The termination of the A-share issuance will not have a substantial impact on the company's normal operations or harm shareholder interests [1]. - The decision was made after friendly consultations with Shenzhen Haiwang Group Co., Ltd. and Guangdong Silk Textile Group Co., Ltd. [1]. Group 2: Business Strategy and Performance - The company has been focusing on restructuring its business, particularly in the medical device sector, while divesting non-core and underperforming assets to enhance operational efficiency [1][2]. - In 2024, the company achieved a revenue of 30.317 billion yuan, maintaining steady growth despite a complex market environment [1]. - The company has completed goodwill impairment provisions, laying a solid foundation for future development [1]. Group 3: Medical Device Business - The company has established a comprehensive supply chain network covering over 20 provinces and cities in China, maintaining long-term stable partnerships with international brands like Siemens and Mindray Medical [2]. - Future plans include expanding the scale of its medical device agency business and deepening strategic cooperation with high-quality domestic and international suppliers [2]. Group 4: Financial Management and Outlook - As of the end of 2024, the company's goodwill was valued at approximately 379 million yuan, allowing it to focus on high-value-added business areas [2]. - The company has successfully completed equity transfers of several subsidiaries, optimizing its asset structure and supporting its transformation [2]. - Although facing short-term financial pressures, the effective release of goodwill risks and the strengthening of core businesses are expected to improve the company's operational status and create sustainable value for investors [2].